GW-0742 – 20MG/ML – 60ML BOTTLE

Low endogenous testosterone levels frequently develop during anabolic growth cycles, because exogenous androgens such as testosterone esters or SARMs (depending on dose) can be suppressive of endogenous testosterone production in Leydig cells.

A link between low testosterone and diabetes is evident considering that men with type 2 diabetes have lower testosterone levels than weight-matched nondiabetic control subjects [1]. In addition, six large clinical studies have shown that low testosterone levels predict development of insulin resistance and type 2 diabetes in men [2]–[6]. Two additional studies demonstrate a positive relationship between total testosterone levels and insulin sensitivity in normal [7] and diabetic men [8]. Furthermore, it is well established in clinical trials that SARM use can temporarily reduce testosterone levels, albeit in a reversible manner [9]. Taken together, it is clear that there is a need to develop new therapies to prevent insulin resistance which may develop as a consequence of therapeutic SARM use.

The development of new drugs for the treatment of insulin resistance is critically important, not only for patients with diabetes but for patients who develop insulin resistance as a consequence of anabolic supplement use, including SARMs. GW-0742, a selective peroxisome proliferator-activated receptor (PPAR)-δ activator, has already been shown to prevent metabolic abnormalities including insulin resistance in skeletal muscle.